Literature DB >> 12588958

DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer.

Russell G Postier1, Megan R Lerner, Stan A Lightfoot, Rick Vannarath, Mary M Lane, Jay S Hanas, Daniel J Brackett.   

Abstract

Computer-assisted analysis of DNA ploidy and nuclear morphology were used to elucidate changes in the cell nucleus that occur during the development of experimental pancreatic cancer. Ductal pancreatic adenocarcinoma was induced in 49 Syrian hamsters by SC injection of N-nitrosobis (2-oxopropyl) amine; twenty hamsters served as controls. Groups of animals were sacrificed every 4 weeks for 20 weeks and adjacent sections of pancreatic tissue were H&E and Feulgen-stained for light microscopy and computer assisted cytometry. Pancreatic ductal cells were classified as normal, atypical, or malignant; tissue inflammation (pancreatitis) was also noted when present. DNA ploidy and nuclear morphology evaluation (Markovian analysis) identified an atypical cell stage clearly distinguishable from either normal or malignant cells; pancreatitis preceded this atypia. The DNA ploidy histogram of these atypical cells revealed a major diploid peak and a minor aneuploid peak. The receiver operator characteristic curve areas for a logistic regression model of normal vs atypical cells was 0.94 and for atypical vs malignant was 0.98, numbers indicative of near-perfect discrimination among these three cell types. The ability to identify an atypical cell population should be useful in establishing the role of these cells in the progression of human pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588958     DOI: 10.1177/002215540305100305

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  4 in total

1.  Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells.

Authors:  Sharmila Manjeshwar; Megan R Lerner; Xiao-Ping Zang; Dannielle E Branam; J Thomas Pento; Mary M Lane; Stan A Lightfoot; Daniel J Brackett; Eldon R Jupe
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

2.  Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.

Authors:  James R Hocker; Russell G Postier; Min Li; Megan R Lerner; Stan A Lightfoot; Marvin D Peyton; Subrato J Deb; Candace M Baker; Travis L Williams; Rushie Jane Hanas; Donald E Stowell; Theresa J Lander; Daniel J Brackett; Jay S Hanas
Journal:  Cancer Lett       Date:  2015-01-28       Impact factor: 8.679

3.  Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic Kras mutation.

Authors:  James R Hocker; Altaf Mohammed; Christopher E Aston; Misty Brewer; Stan A Lightfoot; Chinthalapally V Rao; Jay S Hanas
Journal:  Int J Cancer       Date:  2013-07-01       Impact factor: 7.396

4.  Relationship between nuclear morphometry, DNA content and resectability of pancreatic cancer.

Authors:  Yin-Cheng He; Wei Peng; Jian-Guo Qiao; Jun Cao; Ji-Wei Chen
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.